Recently, it has been demonstrated that the effects of LSD1 inhibitors are particularly robust for small cell lung cancer (SCLC) through promotion of differentiation of tumor-enriched stem-like cells [69]. This evidence concerns the gene KDM1A and small cell lung carcinoma.